Jci_page_head_homepage_01 Jci_page_head_homepage_02
Sohvi Hörkkö, David A. Bird, Elizabeth Miller, Hiroyuki Itabe, Norbert Leitinger, Ganesamoorthy Subbanagounder, Judith A. Berliner, Peter Friedman, Edward A. Dennis, Linda K. Curtiss, Wulf Palinski, Joseph L. Witztum
Published in Volume 103, Issue 1
J Clin Invest. 1999; 103(1):117–128 doi:10.1172/JCI4533
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 4

(a) Immunoassay showing binding of EO autoantibodies and DLH3 to unoxidized PAPC liposomes, OxPAPC liposomes, or POVPC. The liposomes were plated at 10 μg/ml overnight (4°C), and POVPC (10 μg/ml) was plated onto the microtiter wells by evaporation with air for 15 min just before use. Antibodies (10 μg/ml) were then incubated with antigens for 1 h (room temperature). The amount of antibody bound was measured with alkaline phosphatase–labeled goat anti–mouse IgM antibody using chemiluminescent technique. (b) Binding of EO6 to increasing concentrations of PAPC, CuOx-LDL, or POVPC-BSA. Each point is the mean of triplicate determinations. OxPAPC, oxidized PAPC; PAPC, unoxidized L-α1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine; POVPC, 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine.